282 related articles for article (PubMed ID: 9040575)
1. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women.
Beresford SA; Weiss NS; Voigt LF; McKnight B
Lancet; 1997 Feb; 349(9050):458-61. PubMed ID: 9040575
[TBL] [Abstract][Full Text] [Related]
2. Endometrial cancer and hormone-replacement therapy in the Million Women Study.
Beral V; Bull D; Reeves G;
Lancet; 2005 Apr 30-May 6; 365(9470):1543-51. PubMed ID: 15866308
[TBL] [Abstract][Full Text] [Related]
3. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer.
Voigt LF; Weiss NS; Chu J; Daling JR; McKnight B; van Belle G
Lancet; 1991 Aug; 338(8762):274-7. PubMed ID: 1677110
[TBL] [Abstract][Full Text] [Related]
4. Endometrial cancer risk in estrogen users after switching to estrogen-progestin therapy.
Chubak J; Doherty JA; Cushing-Haugen KL; Voigt LF; Saltzman BS; Hill DA; Beresford SA; Weiss NS
Cancer Causes Control; 2007 Nov; 18(9):1001-7. PubMed ID: 17653829
[TBL] [Abstract][Full Text] [Related]
5. Continuous combined hormone replacement therapy and risk of endometrial cancer.
Hill DA; Weiss NS; Beresford SA; Voigt LF; Daling JR; Stanford JL; Self S
Am J Obstet Gynecol; 2000 Dec; 183(6):1456-61. PubMed ID: 11120510
[TBL] [Abstract][Full Text] [Related]
6. Hormone replacement therapy and endometrial cancer.
Emons G; Huschmand-Nia A; Krauss T; Hinney B
Onkologie; 2004 Apr; 27(2):207-10. PubMed ID: 15138357
[TBL] [Abstract][Full Text] [Related]
7. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.
Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108
[TBL] [Abstract][Full Text] [Related]
8. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer.
Strom BL; Schinnar R; Weber AL; Bunin G; Berlin JA; Baumgarten M; DeMichele A; Rubin SC; Berlin M; Troxel AB; Rebbeck TR
Am J Epidemiol; 2006 Oct; 164(8):775-86. PubMed ID: 16997897
[TBL] [Abstract][Full Text] [Related]
9. Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer.
Reed SD; Voigt LF; Beresford SA; Hill DA; Doherty JA; Weiss NS
Am J Obstet Gynecol; 2004 Oct; 191(4):1146-51. PubMed ID: 15507934
[TBL] [Abstract][Full Text] [Related]
10. Low-potency oestrogen and risk of endometrial cancer: a case-control study.
Weiderpass E; Baron JA; Adami HO; Magnusson C; Lindgren A; Bergström R; Correia N; Persson I
Lancet; 1999 May; 353(9167):1824-8. PubMed ID: 10359406
[TBL] [Abstract][Full Text] [Related]
11. Estrogen-progestin replacement therapy and endometrial cancer.
Pike MC; Peters RK; Cozen W; Probst-Hensch NM; Felix JC; Wan PC; Mack TM
J Natl Cancer Inst; 1997 Aug; 89(15):1110-6. PubMed ID: 9262248
[TBL] [Abstract][Full Text] [Related]
12. Risk of endometrial cancer following estrogen replacement with and without progestins.
Weiderpass E; Adami HO; Baron JA; Magnusson C; Bergström R; Lindgren A; Correia N; Persson I
J Natl Cancer Inst; 1999 Jul; 91(13):1131-7. PubMed ID: 10393721
[TBL] [Abstract][Full Text] [Related]
13. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
van Leeuwen FE
Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
[TBL] [Abstract][Full Text] [Related]
14. Cancer issues.
Marsden J; Sturdee D
Best Pract Res Clin Obstet Gynaecol; 2009 Feb; 23(1):87-107. PubMed ID: 19036643
[TBL] [Abstract][Full Text] [Related]
15. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens.
Cushing KL; Weiss NS; Voigt LF; McKnight B; Beresford SA
Obstet Gynecol; 1998 Jan; 91(1):35-9. PubMed ID: 9464717
[TBL] [Abstract][Full Text] [Related]
16. Menopausal hormone use and endometrial cancer, by tumor grade and invasion.
Shapiro JA; Weiss NS; Beresford SA; Voigt LF
Epidemiology; 1998 Jan; 9(1):99-101. PubMed ID: 9430277
[TBL] [Abstract][Full Text] [Related]
17. Hormone replacement therapy and risk of non-fatal stroke.
Pedersen AT; Lidegaard O; Kreiner S; Ottesen B
Lancet; 1997 Nov; 350(9087):1277-83. PubMed ID: 9357407
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT).
Sourander L; Rajala T; Räihä I; Mäkinen J; Erkkola R; Helenius H
Lancet; 1998 Dec 19-26; 352(9145):1965-9. PubMed ID: 9872245
[TBL] [Abstract][Full Text] [Related]
19. Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States).
Newcomb PA; Trentham-Dietz A
Cancer Causes Control; 2003 Mar; 14(2):195-201. PubMed ID: 12749724
[TBL] [Abstract][Full Text] [Related]
20. Use of HRT and the subsequent risk of cancer.
Beral V; Banks E; Reeves G; Appleby P
J Epidemiol Biostat; 1999; 4(3):191-210; discussion 210-5. PubMed ID: 10695959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
